Argot Partners
Highly Engaged Employees
Highly Engaged EmployeesAdvertising Networks · New York, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
767 3rd Ave Fl 34, New York City, New Yo...Phone Number
(212) 600-1902Website
www.argotpartners.comRevenue
$30.6 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
2
1
1
About Argot Partners
Argot Partners is a strategic communications firm specializing in the life sciences sector, offering expertise in articulating complex scientific concepts and business value. The firm provides integrated communications programs tailored to the evolving goals of both private and public life science companies, ranging from preclinical to commercial stages. Their services include strategic counsel and tactical support across various communications disciplines, including investor relations and media engagement. With a team of experienced professionals from diverse backgrounds, Argot Partners aims to deliver impactful messaging to the right audiences.Explore more
Argot Partners Org Chart
MD
Senior Vice President
EH
Senior Vice President
CW
Vice President
VS
Vice President
RP
Vice President
JA
Vice President
JE
Vice President
AC
Vice President
KI
Vice President
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Argot Partners your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Argot Partners is spiking on competitors!
Check if Argot Partners has recently received funding, and reach out quickly before it becomes old news!
Argot Partners, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Argot Partners recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Argot Partners launches new products
Congratulate Masked Content for being promoted to Masked Content at Argot Partners
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Argot Partners has new funding data
Click to see if Argot Partners had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Argot Partners
Find 3 more new buyers
Compare Similar Companies to Argot Partners
Compare insights from companies similar to Argot Partners, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Argot Partners is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Argot Partners is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Argot Partners.
Argot Partners financials insights
Gather financial insights about Argot Partners, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$350K
Argot Partners Tech Stack
A closer look at the technologies used by Argot Partners
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
Person-Based
Left Company
Executive Move
Executive Moves, Left Company
Mergers & Acquisitions (M&A)
Argot Partners News & Media
Deciphera Pharmaceuticals Completes Enrollment in the INVICTUS Pivotal Phase 3 Clinical Study of DCC-2618 in Patients with Advanced Gastrointestinal Stromal Tumors
WALTHAM, Mass.--(BUSINESS WIRE)--$DCPH #GIST--Deciphera completes enrollment in INVICTUS pivotal Phase 3 clinical study of DCC-2618 in fourth-line and fourth-line-plus GIST patients.Ra Pharmaceuticals Elects Bo Cumbo to Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the election of Bo Cumbo to its board of directors. Mr. Cumbo is a veteran of the biotechnology industry and has played strategically important roles in the successful launch of 11 products across multiple organizations and therapeutic categories, including rare neuromuscular diseases, hepatitis, HIV, and cardiovascular disease. “In his more than twenty-year career in the biotechnology and pharmaceutical sAVEO Oncology Announces $2M Milestone Payment from EUSA Pharma Related to German Commercialization of FOTIVDA®
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Oncology (NASDAQ: AVEO) today announced the triggering of a $2 million milestone payment to AVEO from EUSA Pharma. The milestone payment relates to the commercial launch and reimbursement in Germany of FOTIVDA® (tivozanib) as a first line treatment of adult patients with advanced renal cell carcinoma (RCC). In the European Union, Norway and Iceland, tivozanib is indicated for the first line treatment of adult patients with RCC and for adult patients whoNeuralstem Reports Third Quarter 2018 Financial Results and Provides Business Update
- NSI-189 Received Orphan Designation for Treatment of Angelman Syndrome - - Initiated Phase 2 Clinical Trial of NSI-566 for Treatment of Chronic Stroke - - Second-Generation Neural Stem Cell Program NSI-532 Showed Positive Preclinical Results for Alzheimer’s Disease - - Closed $2.1 Million Registered Direct Offering - GERMANTOWN, Md., Nov. 14, 2018 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its
Read more news
Top Advertising Networks Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Argot Partners
Sign Up For FreeTo access detailed company insights
Argot Partners is a strategic communications firm specializing in the life sciences sector, offering expertise in articulating complex scientific concepts and business value. The firm provides integrated communications programs tailored to the evolving goals of both private and public life science companies, ranging from preclinical to commercial s... Read More
